As of 2023, India had approximately 81,000 confirmed cases of Rifampicin Resistant/Multi-Drug Resistant Tuberculosis (RR-/MDR-TB). Forecasts predict a steady increase in cases: 84,800 in 2024, reaching 100,360 by 2028, reflecting rising RR-/MDR-TB challenges.
Year-on-year growth rate is projected as follows:
- 2024-2025: 4.73%
- 2025-2026: 4.42%
- 2026-2027: 4.14%
- 2027-2028: 3.91%
The five-year CAGR is approximately 4.52%, indicating a consistent upward trajectory in RR-/MDR-TB incidence.
Future trends to watch include: advances in TB treatment protocols, resistance surveillance improvements, and policy efforts in public health awareness and healthcare access, which may influence RR-/MDR-TB dynamics significantly in India.
